ocal Tumor Control in Liver Malignancies Treated with Interstitial Brachytherapy (iBT)

Recruiting

• Conditions: C22; Malignant neoplasm of liver and intrahepatic bile ducts

• Registration Number: DRKS00026787
• Lead Sponsor: MU Klinikum der Universität München

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-02-17
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

HCC (Hepatocellular carcinoma) and oligometastatic CRC(Colorectal carcinoma) with interstitial brachytherapy(iBT)

Exclusion Criteria

no treatment interstitial brachytherapy(iBT)
no HCC

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Overall survival

Secondary Outcome Measures

Name	Time	Method
Progression-free survival